Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis

References

• Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 2000;3:243–521. Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 2000;3:243–52
   PubMedGoogle Scholar
• Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 2005;23:243–572. Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 2005;23:243–57
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328–463. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328–46
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:23–374. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:23–37
   Google Scholar
• van der Heijde D, Kalreskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063–745. van der Heijde D, Kalreskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063–74
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, Label and Approval History, HUMIRA® Approval Label Available from http://www.fda.gov/cder/foi/label/2002/adalabb123102LB.htm [Last accessed 15 Jun 2007]6. Food and Drug Administration, Label and Approval History, HUMIRA® Approval Label Available from http://www.fda.gov/cder/foi/label/2002/adalabb123102LB.htm [Last accessed 15 Jun 2007]
   Google Scholar
• Enbrel® package insert. Available from http://www.enbrel.com/pdf/enbrel_pi.pdf [Last accessed 21 Nov 2007]7. Enbrel® package insert. Available from http://www.enbrel.com/pdf/enbrel_pi.pdf [Last accessed 21 Nov 2007]
   Google Scholar
• Food and Drug Administration. Label and approval history, Remicade® approval label. Available from http://www.fda.gov/cder/foi/label/2004/103772s5073lbl.pdf [Last accessed 15 Jun 2007]8. Food and Drug Administration. Label and approval history, Remicade® approval label. Available from http://www.fda.gov/cder/foi/label/2004/103772s5073lbl.pdf [Last accessed 15 Jun 2007]
   Google Scholar
• Ollendorf DA, Massarotti E, Birbara C, Burgess SM. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383–939. Ollendorf DA, Massarotti E, Birbara C, Burgess SM. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383–93
   PubMedGoogle Scholar
• Berger A, Edelsberg J, Li TT, et al. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005;39:2021–510. Berger A, Edelsberg J, Li TT, et al. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005;39:2021–5
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005;53:872–8811. Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005;53:872–88
   PubMed Web of Science ®Google Scholar
• Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:3612. Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
   PubMed Web of Science ®Google Scholar
• Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005;18:21–713. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005;18:21–7
   PubMedGoogle Scholar
• Abarca J, Malone DC, Armstrong EP, et al. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm 2004;10:538–4214. Abarca J, Malone DC, Armstrong EP, et al. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm 2004;10:538–42
   PubMedGoogle Scholar
• Wu E, Chen L, Birnbaum H, et al. Cost of care for patients with rheumatoid arthritis receiving TNF antagonist therapy using claims data. Curr Med Res Opin 2007;8:1749–5915. Wu E, Chen L, Birnbaum H, et al. Cost of care for patients with rheumatoid arthritis receiving TNF antagonist therapy using claims data. Curr Med Res Opin 2007;8:1749–59
   Google Scholar
• Gu NY, Huang XY, Globe D, et al. Methods for measuring dose increase in TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Presented at International Society of Pharmacoeconomics and Outcome Research 12th Annual Meeting, Arlington, Virginia, 19–23 May 200716. Gu NY, Huang XY, Globe D, et al. Methods for measuring dose increase in TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Presented at International Society of Pharmacoeconomics and Outcome Research 12th Annual Meeting, Arlington, Virginia, 19–23 May 2007
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–8317. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–918. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9
   PubMed Web of Science ®Google Scholar